Novartis is planning to file marketing applications for its Alzheimer'sdisease treatment, Exelon (ENA-713), in the European Union, the USA and other world health authorities in the next few weeks.
Exelon is a acetylcholinesterase inhibitor which offers improved efficacy and tolerability over the lead drug in this category, Warner-Lambert's Cognex (tacrine). The dossier is based on the ADENA clinical trials program, which enrolled over 4,000 patients with Alzheimer's disease. ADENA also included the first-ever predominantly European Phase III study to demonstrate significant efficacy in the disease (Marketletter December 2, 1996).
Novartis maintains that Exelon has shown the largest effect on patients' cognitive abilities, such as memory, attention and orientation, than all other Alzheimer's drug studies to date. The drug has not been associated with hepatic, cardiovascular or pulmonary adverse events, or neuromuscular leg cramps, as seen with some other compounds. The most common side effects are nausea, vomiting and diarrhea, which occur most frequently during titration dosing. Exelon can also be taken concurrently with other drugs used in Alzheimer's patients, according to Novartis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze